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Abstract 
Immunohistochemistry (IHC) is a widely-tested, low-cost and rapid ancillary technique available in 
all laboratories of pathology. This method is generally used for diagnostic purposes, but several 
studies have investigated the sensitivity and specificity of different immunohistochemical 
antibodies as a surrogate test in the determination of predictive biomarkers in non-small cell lung 
cancer (NSCLC), particularly for Epidermal Growth Factor Receptor (EGFR) gene mutations, 
Anaplastic Lymphoma Kinase (ALK) gene and ROS1 rearrangements. In this review, a critical 
examination of the works comparing the consistency of IHC expression and conventional 
molecular techniques to identify genetic alterations with predictive value in NSCLC is discussed. 
Summarizing, data on sensitivity and specificity of antibodies against ALK and ROS1 are very 
consistent and time is comes to trust in IHC at least as a cost-effective screening tool to identify 
patients with rearranged tumors in clinical practice. On the other hand, mutant-specific antibodies 
against EGFR demonstrate a good specificity but a low-to-fair sensitivity, then raising some 
cautions on their employment as robust predictive biomarkers. A brief comment on preliminary 
experiences with antibodies against BRAF, RET, HER2 and c-MET is also included. 
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Introduction 
More than half of non-small cell lung cancer (NSCLC), in particular adenocarcinoma histologic type, 
show genetic alterations involving oncogenic drivers leading to aberrant activation of tyrosine 
kinases acting as molecular targets for selective inhibitors.1,2 
The presence of these genetic alterations is the unique most important finding in predicting 
effectiveness of specific targeted therapies.3 Most important, patients with adenocarcinomas 
harbouring epidermal growth factor receptor (EGFR) mutations or Anaplastic Lymphoma Kinase 
(ALK) and ROS1 rearrangements have a significant disease-free survival when compared with 
conventional chemotherapy. 4-10 This revolutionary therapeutic approach in patients with NSCLC 
generally requires a drug specific “companion diagnostic” test to select patients with tumors 
harboring genetic alterations. 11 Of note, some “companion diagnostics” have been approved 
differently in various countries.12-14 
In brief, approximately 10% to 40% of lung adenocarcinomas (mainly depending on ethnicity with 
highest frequency in Asiatic patients) harbor a EGFR mutation and about 90% of these mutations 
occur in exons 19 (E746-A750 deletion and other short in-frame variants of this deletions in exon 
19) and 21 (leucine to arginine substitution at amino acid 858, L858R).1,2 Less common mutations 
predicting a minor clinical response to EGFR tyrosine kinase inhibitors (TKI) occur in exons 18 and 
20.15-17 Overall, EGFR mutations are the best predictors of efficacy when adopting selective TKIs, 
namely gefitinib, erlotinib and afatinib. 4-6 Several PCR-based DNA extractive methods are available 
and accepted to detect EGFR mutations, although there is a wide range in terms of sensitivities 
among various methodologies, significantly leading to quite different results.13,14,18,19 
About 5-7% of lung adenocarcinomas harbor a rearrangement of ALK gene, particularly through an 
intrachromosomal inversion with EML4-ALK gene and other genes, then leading to a fusion 
product associated with ALK protein overexpression.12 Clinical features, (e.g., young age, 
 4 
non/light-smoking habit, adenocarcinoma with cribriform/signet ring cell pattern) cannot reliably 
identify patients with ALK-positive tumors. 20 Fluorescence in-situ hybridization (FISH) using break-
apart probe is currently considered the gold standard for detection of ALK rearrangement, since 
clinical trials with the dual MET and ALK-inhibitor crizotinib are based on ALK FISH detection.7-9 
More recently, the rearrangement of ROS1 gene has been identified in a small subset (about 1-2%) 
of lung adenocarcinomas.21 Detection of ROS1 rearrangement in the recent clinical trial by Shaw et 
al. 10 was performed using a break apart probe with FISH assay.  
Other promising gene alterations involving BRAF, HER2, RET and c-MET seem to predict novel 
therapeutic scenarios in NSCLC. 2,22 
Although immunohistochemistry (IHC) is the main ancillary technique in pathology labs and it has 
been largely demonstrated that some antibodies against EGFR, ALK and ROS1 can indirectly detect 
the presence of gene alterations with high specificity and fair-to-high sensitivity, this technique is 
not validated to directly select patients undergoing specific targeted therapies in NSCLC, as instead 
happen in breast and gastric cancer with HER2 detection. 23 
Although generally poorly-appreciated in the molecular biology community, IHC is a rapid, cheap 
and well-known assay that does not require huge tumor cell content and perform quite well even 
in degraded tissue (e.g., decalcified bone tissue) or cytology samples (Table 1). 
In the present review, we aimed at summarizing the characteristics and the performance rate in 
terms of sensitivity and specificity of the antibodies acting as possible surrogates to predictive 
molecular tests, also discussing the future landscape in which IHC could be adequately adopted as 
screening as well as confirmatory test to detect predictive biomarkers in routine clinical practice.  
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1. EGFR mutations 
 
The finding of an activating EGFR mutation in NSCLC is the best single predictor of efficacy using 
selective tyrosine kinase inhibitors (TKI), while total EGFR expression at immunohistochemistry 
and EGFR FISH assay did not demonstrate to be reliable predicting biomarkers. 3 Various activating 
EGFR mutations have been reported in exons 18, 19, 20 and 21, but about 90% of EGFR mutations 
in NSCLC involve in-frame deletions of exon 19 (E746-A750 del and variants) and point mutation 
L858R in exon 21. 13,18,19 These mutations are also significantly related to a better and prolonged 
clinical response to EGFR TKI (particularly exon 19 deletions), 16 although other less drug-sensitive 
mutations may occur in exon 18 (G719X), exon 20 (insertions) and exon 21 L861X at a much lower 
frequency. Despite the great variability of the detection rate sensitivity, all PCR-based tumor DNA 
extractive methods are basically accepted in determination of EGFR mutations and represent 
validated techniques in all guidelines proposed from different scientific societies in various 
countries. 13,18,19 
Detection of EGFR mutations significantly increase when using more sensitive detection 
methodologies. 13 Supporting this view, Won et al. 24 recently demonstrated the presence of 
additional activating EGFR mutations when passing from direct sequencing to mutant-enriched 
Next Generation Sequencing (NGS) in a population of ALK-positive tumors, finally evidencing EGFR 
mutations in 15.4% of ALK-rearranged NSCLC (14 out of 91). The presence of minor clones of EGFR 
mutated tumor cells in ALK-positive NSCLC might explain the occurrence of dual-positive tumors 
and the different detection rate of EGFR mutations due to variable sensitivity of various methods 
used in the study. Again, Zhou et al. 25 detected 30% of false negative EGFR mutations using the 
Scorpion amplification refractory mutation system (ARMS) in a population of wild-type cases 
originally investigated with direct sequencing. 
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In 2009, Yu et al. 26 developed two rabbit monoclonal antibodies selectively directed against E746-
A750 deletion in exon 19 (clone 6B6, Cell Signaling Technology; also known as clone SP111 from 
Ventana Medical Systems, Inc., Tucson, AZ, USA) and the L858R point mutation in exon 21 (clone 
43B2 from Cell Signaling Technology; also known as clone SP125 from Ventana Medical Systems) 
demonstrating high sensitivity (88% and 92%, respectively) and specificity (100% and 99%, 
respectively) of these antibodies in recognizing the relevant EGFR mutations. However, discordant 
results have been reported in different studies investigating the adequacy of IHC in detecting EGFR 
mutations when compared with standard DNA sequencing methods.27-53 
Provided that in normal routine practice DNA sequencing analysis should always be considered the 
gold standard, 54 the main advantages to use mutation-specific antibodies in detecting EGFR 
mutations may be the following: 1. in critical patients requiring a rapid determination of EGFR 
mutations; 2. in tiny biopsy or scarce cytologic specimens; 3. in poorly-preserved or degraded 
tumor tissue (e.g., decalcified bone tissue), precluding reliable results, and then false negative 
cases, when using low-sensitive DNA extractive techniques. 
As summarized in Table 2, the sensitivity of these antibodies is very variable (ranging from 30% to 
100% with a mean value between 60% and 70%), mainly depending on the cut-off scoring system 
to quote immunoreactivity, while the specificity is excellent (overall >90%). Of course, these 
mutant-specific antibodies do not stain tumors harboring EGFR mutations different from E746-
A750del and L858R. 
Basically, the sensitivity of mutant-specific antibodies to detect all EGFR mutations range from 
about 40% to 60%. Thus, EGFR mutant-specific antibodies cannot replace conventional DNA 
sequencing molecular methods in detecting this predictive biomarker. Nevertheless, these 
antibodies should represent a valid adjunct to molecular techniques when specimens contain a 
low cellularity or poorly-preserved tumor cells. In fact, tumor cell showing consistent expression 
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(score 2+/3+) for these antibodies firmly indicate the presence of the relevant EGFR mutation 
(Figures 1 and 2). 
 
2. ALK rearrangement 
 
In 2007, Soda et al.55 first documented a small inversion within chromosome 2p resulting in the 
formation of a fusion gene comprising EML4 and ALK in NSCLC. The chromosomal rearrangement 
of the 3’ kinase domain of ALK most often involve the N-terminal portion of Echinoderm 
Microtubule-associated protein-Like 4 (EML4) gene, but less common 5’ fusion partners have been 
identified including Kinesin Family member 5B (KIF5B), TRK-fused gene (TFG), Kinesin Light Chain 1 
(KLC1) and others. 20 
This gene alteration represented the molecular target for the double MET and ALK inhibitor PF-
02341066 (crizotinib). The clinical efficacy of crizotinib in patients with ALK rearranged NSCLC was 
then demonstrated in various clinical trials, 7-10 both in heavily-pretreated and naïve (first line) 
settings. Despite patients with ALK-rearranged tumor have some peculiar characteristics 
(never/light smokers, younger age, adenocarcinomas histotype with mixed patterns including 
acinar and cribriform architecture and signet-ring cells), none of these clinico-pathologic features 
may reliably predict the response to ALK inhibitors (crizotinib, ceritinib). 20,56,57 According to the 
Food and Drug Administration (FDA), in United States the use of crizotinib is limited to ALK-
positive tumors when detected by the Abbott Vysis ALK break apart Fluorescent in situ 
Hybridization (FISH) probe kit. Tumors are considered positive when 15% of cells (couting at least 
50 tumor cells) show a positive signal (either as single red spot or break apart of the colored 
probes indicating delection or inversion of ALK gene, respectively). Although clinically validated, 
FISH test is laborious, relatively expensive and requires a good expertise. In addition, a not 
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insignificant rate of tumors also show borderline results with 10-14% of positive cells. 58-60 The 
European Medicines Agency (EMA) approved the use of crizotinib in all ALK-positive patients 
tested with a validated method without restriction to FISH technique. While the presence of more 
than twenty ALK gene fusions with EML4 and other ALK gene fusion partners seems to preclude 
the use of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) in routine practice, the 
demonstration of ALK protein expression by immunohistochemistry (IHC) seems to open an 
important screening test to detect ALK-positive NSCLC. 12 
Since ALK protein is not expressed in normal adult lung tissue, IHC appears a robust alternative 
method in identifying lung cancers harbouring ALK rearrangement. Provided that IHC is not 
expensive and of rapid execution, it has the great advantage to be the most used ancillary 
technique in all laboratories of pathology. The main problem is that the cellular content of ALK 
protein in ALK rearranged NSCLC tumor cells is much lower that that observed in ALK-lymphomas. 
61 Then, the concentration of the primary antibody against ALK should be increased and the 
positive signal needs improvement by using appropriate detection and visualization kits to 
increase the inter-observer reproducibility. Despite different protocols and primary antibody 
clones, the results comparing ALK detection by IHC and FISH are quite good, if not excellent (Table 
3). 62-100 
In particular, it is important to underline that consistent positivity (score of intensity 2+ and 3+) 
with ALK at IHC is almost always associated with a positive FISH test and, most important, all 
negative cases at IHC are basically negative at FISH analysis (Figure 3). While it is quite exceptional 
to have ALK IHC negative and FISH positive cases, about 1-2% of IHC positive and FISH negative 
cases have been well-documented and these cases do respond to ALK inhibitor. 101-104 
The main concerns about the use of IHC as screening tool in detecting ALK-positive lung tumors 
rely on the fact that: 1. clinical trials with crizotinib refer only to positive patients with FISH test; 2. 
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the sensitivity in detecting ALK tumors may depend on different clones and detection systems; 3. 
the lack of complete interobserver reproducibility among pathologists when using 4-tier scoring 
systems and low sensitivity antibody clones. 
However, several experiences with FISH also indicate that this assay may give false positive and 
negative results as well as a significant rate of not interpretable results. 65,69,76 Among different 
ALK antibodies (clones ALK-1, 5A4 and D5F3) investigated to detect ALK by IHC, the clone 5A4 has 
been validated by the European Thoracic Oncology Platform (ETOP) consortium, 85 while the clone 
D5F3 has been included in the validated test by Ventana Medical System. Inc. and confirmed in 
several works. 105,106 
The use of antibodies with high sensitivity to ALK protein is entirely cost-effective as screening test, 
saving at least 95% of usefulness FISH tests with the certainty to do not left behind true ALK-
positive patients. 81.97,107,108 In addition, ALK IHC test is very helpful in small biopsies characterized 
by a limited number of tumor cells. 
The limited sensitivity reported in preliminary reports is overridden by more recent works that 
highlight a almost complete correlation between IHC and FISH methods, particularly when using 
clones 5A4 and D5F3 coupled to an adequate detection kit. 85,105,106,108 Needless to say that since 
lung cancer generally has a low expression of ALK protein at a cytoplasmic and/or membrane level 
when compared with ALK lymphomas, and weak staining (score 1+) may be associated with a ALK-
rearranged tumor, all these cases require a confirmatory determination using FISH assay. 
Finally, some novel ALK fusion gene (e.g., KIF5B-ALK) were identified by IHC in cases originally 
tested negative at FISH analysis. 68 
Application of adequate external controls in each bath, the use of standardized protocols 
incorporating the correct choice of antibody clone and detection kit as well as the participation to 
external quality control assurance programs should always considered to ensure rigorous 
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immunohistochemical results in routine practice, providing an effective integration of IHC with 
FISH testing. 76,106,108 
Selinger et al. 70 recently reported 100% specificity between IHC and FISH testing 594 resected 
NSCLCs with either ALK1, 5A4, D5F3 clones. IHC also evidenced 6, 11 and 6 ALK + cases using ALK1 
(5 with 1+ and 1 with 2+ score), 5A4 (10 with 1+, 1 with 2+ score) and D5F3 (3 with 1+, 2 with 2+ 
and 1 with 1+ score), respectively.  
Minca et al. 76 demonstrated 100% sensitivity and specificity of D5F3 clone using the Ventana 
automated immunostainer BechMark XT with the OptiView detection system on 249 informative 
NSCLCs diagnosed on formalin-fixed paraffin-embedded and Thin-Prep matched specimens. In 
addition, in 55 not informative FISH samples, IHC was the sole method detecting ALK positivity in 3 
cases. Narrow signal separation of probes, uninformative cases due to scarce number or poor 
preservation of tumor cells, challenging identification of tumor cell morphology in biopsy with 
confounding features (i.e., crash artifacts, the presence of a rich inflammatory infiltrate, a close 
admixture of normal salivary gland structures) (Figure 4) do represent important factors 
precluding a reliable examination of specimens submitted to FISH test. Uninformative results in 
this study were significantly (p<0.001) lower in IHC-tested samples (4%) than in FISH-tested cases 
(26%),76 similarly to what observed in the study by McLeer-Florin et al.65 
While all used ALK clones show an excellent specificity, the clone ALK1 is characterized by a 
moderate sensitivity ranging from 60% to 90% with a relatively low intensity of staining. When 
using a less sensitive clone, the results could be improved by “high-sensitivity” pathologists 
carefully noticing all staining shadows (Figure 5). As a rule, the less sensitive clone is adopted, the 
more sensitive should be the pathologist examining ALK test on IHC. 
By contrast, sensitivity and specificity of studies with clone 5A4 are quite consistent ranging from 
95% to 100%.  Studies employing clones ALK1 and 5A4 used a four-tier scoring system (from 0-
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negative to 1+-weak, 2+-moderate, 3+-strong intensity staining), somehow complicating the inter-
observer reproducibility. The binary system adopted when using the high-sensitivity D5F3-based 
kit proposed by Ventana clearly facilitate ALK determination by IHC even in the hands of less 
expert pathologists. 105,106,108 
Reviewing the last 153 consecutive screened lung adenocarcinomas (unpublished observations), 
the sensitivity and specificity of the clone ALK1 adopting the OptiView detection kit and the 
automated immunostainer BenchMark XT (Ventana Medical Instruments, Tucson, AZ, USA) are 
100% and 96%, respectively. Eighteen ALK-positive cases (11.8%) were identified at IHC and 12 at 
FISH assay (7.8%). All FISH positive cases showed moderate-to-strong expression at IHC level, 
while among the 6 discordant cases 5 revealed a weak intensity (score 1+) and 1 with a moderate 
(2+ score) intensity showed gene amplification at FISH test. In addition, other 27 randomly 
selected ALK negative cases at IHC were entirely negative also with FISH. Of note, 3 out of 12 ALK-
positive cases had a concomitant EGFR (1 case) or KRAS (2 cases) mutation using MALDI-TOF 
methodology, according to other experiences. 24,86 
Practically speaking, IHC is a likely accessible, low-cost, rapid and widely informative technique to 
detect ALK status in NSCLC. High-sensitivity IHC protocols (particularly when using the clone D5F3 
and OptiView amplification kit) are quite consistent when compared to FISH results and should be 
introduced as validated screening test to detect ALK positive patients requiring a confirmatory 
FISH test in a limited NSCLC population. 
 
3. ROS1 
 
ROS1 is a receptor tyrosine kinase involved in tumor cancerogenesis of different tumors. The 
rearrangement of ROS1 with other fusion genes, such as CD74, FIG, EZR and solute carrier protein 
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34A2 (SLC34A2), is the oncogenic driver in a subset (1-2%) of NSCLC, particularly of 
adenocarcinoma subtype. 109-110 Identification of patients with NSCLC harbouring ROS1 
rearrangement in a recent clinical trial with the TKI crizotinib has been performed with a break 
apart FISH assay, demonstrating a dramatic objective clinical response in 72% of cases. 10 However, 
as with ALK, all ROS1 rearrangements may be easily detected at the immunohistochemical level 
with the specific rabbit monoclonal antibody D4D6. 111-113 ROS1 expression seems to be mutually 
exclusive with ALK, but a subgroup of ALK and ROS1 positive NSCLC may show EGFR activating 
mutations detected in the same tumor cells using molecular techniques and EGFR mutant-specific 
antibodies. 114-116 
Recent studies have confirmed the validity of the clone D4D6 to detect ROS1 rearrangement when 
IHC assay was compared to FISH test (Table 4). 117-120 Basically, all ROS1 FISH-positive cases 
showed a consistent (moderate to strong and diffuse) expression of ROS1 protein. 111-113,117-120 On 
one side, all FISH-positive NSCLC are well-recognized by IHC assay reaching 100% of sensitivity, but 
a subset of non-rearranged tumors are IHC-positive leading to a moderate specificity (from 80% to 
95%).111-113,117-120 This is particularly true when quoting as positive also tumor showing weak 
immunoreactivity (score 1+) in a limited fraction of tumor cells. Adopting more rigorous and solid 
scoring systems considering IHC-positivity only tumors with moderate-to-strong intensity signal 
(score 2+/3+) in more than 50% of tumor cells, the specificity of ROS1 clone D4D6 becomes quite 
consistent (>95%). 117-120 
While different previous studies have demonstrated the validity of IHC method in terms of 
specificity and sensitivity to identify ROS1-rearranged NSCLC, a recent work by Cha et al. 119 
highlighted some false positive tumors in ever-smokers. By contrast, Boyle et al. 111 recently 
demonstrated that ROS1 IHC assay has an absolute sensitivity and specificity when compared with 
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FISH and reverse transcriptase polymerase chain reaction (RT-PCR) using an optimized scoring 
system (H-score >100) (Figure 6). 
Taking into account all previous data, IHC screening with ROS1 clone D4D6 seems to be reasonably 
robust to be adopted as a practical, rapid and cost-effective screening tool in detecting ROS1-
rearranged NSCLC, then limiting the number of cases to undergo confirmatory FISH assay. 
 
4. Others (BRAF mutations, RET rearrangement, HER2 mutations, c-MET expression)  
 
BRAF mutations occur in 1-3% of patients with lung adenocarcinoma and occur more commonly in 
current and former smokers. 121,122 BRAF encodes for a nonreceptor serine/threonine kinase, 
activated downstream of the Ras protein. The great majority of BRAF mutations occur in the 
hotspot transversion mutation T1799A at exon 15, leading to the amino acidic substitution of 
V600E. 121,122 However, in NSCLC a wide range of other missense mutations (non-V600E) have been 
detected in exons 11 and 15. 121,122 The incidence of BRAF mutations other than V600E is 
significantly higher in lung cancer than in other extrapulmonary malignancies. 121,122 
The reported BRAF mutations by Paik et al. 121  were V600E (50%), G469A (39%), and D594G (11%). 
In the work by Marchetti et al. 122 56.8% mutations  were V600E, and 43.2% were non-V600E. All 
non-V600E mutations were found in smokers. 
The V600E mutation-specific antibody (clone VE1) has been recently developed. 123 This clone 
perfectly match with V600E BRAF mutations in melanoma and papillary thyroid carcinoma. 
There is a unique study by Ilie et al. 124 demonstrating VE1 expression in 19 out of 21 (90%) BRAF 
V600E mutated adenocarcinomas. As expected, this mutant-specific antibody failed to stain all 
other 10 non-V600E mutations identified in the work. 
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HER2/EGFR-2 mutations characterize a subset of NSCLC (about 3%), particularly in non-smoking 
younger patients with adenocarcinoma subtype. 125 
To date, most of HER2 mutations detected in NSCLC were in-frame insertions of exon 20 with 
duplication of amino acids YVMA at codon 775 (A775_G776insYVMA). 125,126 However, neither FISH 
test nor IHC consistently matched with HER2 mutations, then appearing inconsistent tools in 
predicting HER2 mutated adenocarcinomas. Given the similarity of mutational events, it could be 
that a mutant-specific antibody will be developed in the next future to identify HER2 mutations in 
lung adenocarcinoma at IHC level. 
The RET (rearranged during transfection) proto-oncogene is located at 10q11.2 and encodes a 
receptor tyrosine kinase. 127 The RET protein is lacking in lung tissue and RET rearrangement has 
been recently identified in NSCLC. 128-133 
A subset (1-2%) of lung adenocarcinomas harbour fusion of the KIF5B (kinesin family 
member 5B) gene to the RET (rearranged during transfection) gene or other RET gene fusions, 
namely TRIM33-RET, NCOA4-RET, and CCDC6-RET. A clinical response has been demonstrated 
using RET inhibitors in RET fusion-positive lung adenocarcinomas. 134,135 
In a recent study, Lee et al. 133 showed that 16% (15 out of 94) of EGFR/KRAS/ALK triple-negative 
lung adenocarcinomas harboured RET rearrangement. In contrast to previous studies, 129,132 the 
authors demonstrated moderate-to-strong immunoreactivity for RET at IHC (clone 134100, 
Abcam) in all 15 RET fusion-positive cases 100% of sensitivity), while a focal staining was observed 
also in 10 out of 79 (12%) RET fusion-negative cases (89% of specificity).  
Adenocarcinoma of the lung harboring RET-rearrangement seem to have a peculiar morphology 
with crobroform pattern, lymphangitic spread and psammoma bodies. 136 
While the phase III trial with Ornatuzumab (Genentech/Roche) failed to demonstrate a significant 
prolonged progression-free survival in the group of patients treated with Ornatuzumab plus 
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erlotinib versus erlotinib alone, IHC with the clone SP44 still remain the most promising biomarker 
in predicting clinical response to humanized monoclonal antibody MetMAb, particularly when 
tumor express MET with at least 2+ intensity in more than 50% of tumor cells. 137 
At the moment, FISH assay demonstrated a poor prognosis in amplified NSCLC, but it is inferior to 
IHC in this setting and c-MET activating mutations does occur only in sporadic NSCLC. 
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Closing remarks 
 
- DNA sequencing and FISH assay are universally considered the gold-standard for selecting 
patients for TKI therapy, although often characterized by long turn-around time, tissue 
insufficiency, difficulty in interpretation and equivocal results 
- IHC represents a fast and cost-effective “in-situ” proteomic assay that can reversely and 
effectively detect mutations and rearrangements  
- EGFR mutant-specific antibodies have a high specificity (strongly expression/score 3+ does 
not require molecular confirmation) but low/fair sensitivity (negative staining requires 
molecular testing, also microdissecting IHC-stained tumor cells) 
- IHC is a cost-effective widely available method that could be used to screen patients with 
lung cancer for ALK and ROS1 rearrangements 
- Standardized  protocols clearly defining the best antibody clone, detection kit and scoring 
system to be adopted should be organized and widely shared 
- Practical algorithms including IHC screening for ALK and ROS1 and subsequent FISH assay 
confirmation actually represent the best way in terms of adequacy, rapidity and cost-
effectiveness to specifically identify tumors harbouring these genetic rearrangements 
without loosing patients with equivocal FISH setup 
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Figure Legend 
Figure 1. A case of liver metastasis from lung adenocarcinoma (A, H&E stain) harboring exon 19 
E746-A750 del EGFR mutation detected using mutant-specific antibody (B and insert, 
immunohistochemistry with clone 6B6) and negative for mutant-specific antibody against L858 
EGFR mutation (C, immunohistochemistry, clone 43B2) 
Figure 2. A lung adenocarcinoma diagnosed on cell block (A, H&E stain) expressing mutant-specific 
antibody against L858 EGFR mutation (B, immunohistochemistry, clone 43B2), but not with 
mutant-specific antibody against exon 19 E746-A750 del EGFR mutation (C, immunohistochemistry 
with clone 6B6). 
Figure 3. Pulmonary adenocarcinoma (A, H&E stain) strongly expressing ALK protein with clone 
D5F3 (B, immunohistochemistry) and clone 5A4 (C, immunohistochemistry). 
Figure 4. A small aggregate of tumor cells (< than 50 did not permit a reliable FISH test) of 
adenocarcinoma in a bronchial biopsy (A, H&E stain) strongly expressing ALK (B, clone ALK1 
immunohistochemistry). Few tumor cells of adenocarcinoma intermingled with inflammatory cells 
in a cell block (C, H&E stain) and bone metastasis from adenocarcinoma (D, H&E stain) may 
complicate determination of ALK rearrangement by FISH test). 
Figure 5. A poorly-differentiated lung adenocarcinoma showing a weak positivity for ALK (clone 
ALK1, immunohistochemistry) resulted ALK rearranged at FISH assay (insert). 
Figure 6. A lung adenocarcinoma (A, H&E stain) consistently expressing ROS1 (B, clone D4D6 
immunohistochemistry). 
Table 1. Summary of immunohistochemical antibodies possibly acting as surrogates to recognize predictive 
biomarkers conventionally detected by DNA sequencing or FISH 
 
 
Antibody Clone Biomarker Main Pro Main Cons Validation in 
clinical practice 
EGFR 6B6 EGFR 
mutations 
 
- rapid 
- application poor 
material 
- low cost 
- restricted to exon 19 
delE746-A750 
- not clinically validated 
Not yet 
EGFR 43B2 EGFR 
mutations 
 
- rapid 
- application on poor 
material 
- restricted to exon 21 
L858R 
- not clinically validated 
Not yet 
ALK ALK1 ALK 
rearrangement 
 
- rapid 
- application on poor 
material 
- screening tool 
- good specificity 
- low cost 
- low/moderate 
sensitivity 
- not clinically validated 
Possible use as 
screening method 
ALK 5A4 ALK 
rearrangement 
 
- rapid 
- application on poor 
material 
- screening tool 
- good sensitivity & 
specificity 
- low cost 
- not clinically validated Possible use as 
screening method 
ALK D5F3 ALK 
rearrangement 
 
- rapid 
- application on poor 
material 
- screening tool 
- high sensitivity & 
specificity 
- low cost 
- not clinically validated Possible use as 
screening method 
ROS1 D4D6 ROS1 
rearrangement 
 
- rapid 
- application on poor 
material 
- screening tool 
- high sensitivity & 
specificity 
- low cost 
- not clinically validated Possible use as 
screening method 
BRAF VE1 BRAF 
mutations 
 
 
- rapid 
- application on poor 
material 
- screening tool 
- low cost 
- restricted to exon 15 
V600E 
- limited experience in 
lung cancer 
- not clinically validated 
Not yet 
RET - RET 
rearrangement 
 - not clinically validated Not yet 
Table 2. Summary of all previous studies using EGFR E746-A750 deletion specific (clone 6B6) and EGFR 
L858R mutant-specific (clone 43B2) (Cell Signaling Technology, Inc.) 
 
Reference Case n Molecular test of 
comparison 
Sensitivity 
& Specificity 
Exon 19 
Sensitivity 
& Specificity 
Exon 21 
Overall 
Sensitivity & 
Specificity 
Yu et al. 
2009 
40 adc (h) Direct 
Sequencing 
N.A. 
N.A. 
N.A. 
N.A. 
92% 
99% 
Brevet et al. 
2010 
218 adc 
(h/TMA) 
PCR-RFLP 85% 
99% 
95% 
99% 
75% 
99% 
Simonetti et al. 
2010 
78 NSCLC (h) Direct 
Sequencing 
63% 
100% 
93% 
100% 
78% 
100% 
Kawahara et al. 
2010 
60 NSCLC (h) Direct 
Sequencing 
77% 
100% 
91.5% 
100% 
85% 
100% 
Nakamura et al. 
2010 
20 adc (h) PNA-LNA 90% 
100% 
100% 
100% 
90% 
100% 
Kato et al.  
2010 
70 NSCLC 
(h/TMA) 
Direct 
Sequencing 
50% 
100% 
75% 
97% 
44% 
99% 
Ilie et al. 
2010 
61 adc 
(h/TMA) 
Direct 
Sequencing 
89% 
N.A. 
No exon 21 
mutations 
 
89% 
N.A. 
Ambrosini-Spaltro 
et al. 
2012 
33 adc (h) Direct 
Sequencing 
50% 
100% 
83% 
100% 
61% 
100% 
Tsai et al. 
2012 
78 (cell block) Direct sequencing 58% 
95% 
71 
86% 
69% 
79% 
Hasanovic et al. 
2012 
145 adc (c + core 
biopsy and 
decalcified bone 
biopsies) 
Rapid PCR-based 
method 
N.A. N.A. - 
100% 
Kawahara et al. 
2011 
24 adc (c) Direct 
Sequencing 
100% 
100% 
100% 
100% 
100% 
100% 
Kitamura et al.  
2010 
238 NSCLC 
(h/TMA) 
Direct 
Sequencing 
40% 
99% 
36% 
97% 
47% 
96% 
Kozu et al. 
2010 
577 adc (h) HRMA 42% 
99.5% 
76% 
98% 
63% 
70% 
Wu et al. 
2011 
143 adc 
(h) 
Direct 
Sequencing 
73% 
95% 
88% 
77% 
83% 
75% 
Fan et al  
2013 
169 adc (h) Direct 
Sequencing 
74% 
99% 
93% 
100% 
- 
Jiang et al. 
 
399 NSCLC (h/c) TaqMan PCR 
assay 
80% 
85% 
76% 
92% 
- 
Abbreviations: adc, adenocarcinoma; NSCLC, non-small cell lung cancer; h, histologic samples; c, cytology; 
TMA, tissue microarray; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism 
assay; HRMA, high resolution melting analysis; PNA-LNA, peptide nucleic-acid locked nuclei acid-PCR; N.A., 
not available; N.P., not performed. 
 
Hofman et al. 
2012 
154 adc (h) Direct 
Sequencing 
55% 
97% 
24% 
98% 
- 
Ho et al. 
2013 
445 adc (h) Direct 
Sequencing 
ARMS 
57% 
100% 
68% 
95% 
- 
Cooper et al. 
2013 
204 adc (h) Sequenom 100% 
98% 
86% 
98.5% 
- 
Xiong et al. 
2013 
50 adc (h) QIAamp 59% 
100% 
81% 
97% 
- 
Seo et al. 
2014 
240 adc (h) Direct 
Sequencing / 
Pyrosequencing 
80.5% 
90% 
71% 
99% 
- 
Ping W et al. 
2014 
215 adc (h) Direct 
Sequencing 
N.P. 88% 
100% 
- 
Bondgaard et al.  
2014 
210 NSCLC (h) TheraScreen 63% 
99% 
80% 
98% 
- 
Allo et al. 
2014 
247 adc (h) Sequenom 
Direct 
Sequencing 
83% 76% - 
Houang et al. 
2014 
326 non-squamous 
(h) 
Direct 
Sequencing 
Sequenom  
Cobas-Roche 
63% 
100% 
96% 
92% 
58% 
92% 
Wang et al. 
2014 
115 NSCLC (h/c) ARMS 98.5% 
100% 
100% 
100% 
- 
Table 3. Summary of studies comparing ALK detection by IHC and FISH  
 
Reference Cases n Antibody 
Clone 
(Source) 
Detection  
System 
% FISH + & 
% IHC + 
Sensitivity 
 
Specificity 
Boland et al. 
2009 
185 adc (h) 
150 sqc (h) 
ALK1 
(Dako) 
- 1.8%/1.8% 100% 100% 
Mino-
Kenudson 
et al. 
2010 
153 adc (h) D5F3 
(CST) 
ALK1 
(Dako) 
EnVision Flex+ 14.3% / n.a. 100% 
 
67% 
99% 
 
97% 
McLeer-Florin 
et al. 
2011 
441 adc (h) 5A4 
(Novocastra) 
Ultraview n.a. / 6.5% 95% 100% 
Paik et al. 
2011 
465 NSCLC 
(395 adc) 
(h) 
5A4 
(Novocastra) 
Ultra-view 3.8% / 7.5% 
6.8% (adc)  
100% 96% 
Yi et al. 
2011 
101 adc (h) ALK1 
(Dako) 
Advance 10% / 11% 90% 98% 
Paik et al. 
2012 
735 NSCLC 
(h) 
5A4 
(Novocastra) 
Ultraview 3.8%/7.5% 100% 96% 
Rimkunas et 
al.  
2012 
556 NSCLC 
(h) 
D5F3 (CST) EnVision Flex+ 4%/4% 100% 100% 
Park et al. 
2012 
262 non-
sqc (h) 
5A4 
(Novocastra) 
Bond Polymer 
Refine 
9.5%/10.7% 100% 99% 
Martinez et al. 
2013 
80 NSCLC 
(h/c) 
D5F3 
(CST) 
Ultraview 7% 83% 100% 
Selinger et al. 
2013 
594 NSCLC 
(h) 
ALK1 (Dako) 
5A4 
(Novocastra) 
D5F3 (CST) 
Envision Flex + 
Ultraview 
 
Optiview 
1% 100% 99% 
Zhang et al. 
2013 
173 NSCLC 
(h)/selected 
D5F3 (CST) - 35.5%/35.7% 100% 100% 
Sholl et al. 
2013 
186 adc (h) 5A4 
(Novocastra) 
 
EnVision 
Flex + 
8% 93% 100% 
Tuononen et 
al. 2013 
87 NSCLC 
(h) 
5A4 
(Novocastra) 
 
Optiview 6%/6% 100% 100% 
Han et al. 
2013 
139 non-
sqc (h) 
selected  
D5F3 
(CST) 
- 32.6%/33% 98% 97% 
Ying et al. 
2013 
196 adc (h) 
selected 
D5F3 
(CST) 
Optiview 32%/33% 100% 98% 
Minca et 
al.2013 
265 NSCLC 
(h/c) 
D5F3 
(CST) 
Optiview 12.8% 100% 100% 
Takamochi et 
al. 2013 
360 NSCLC 
(h) 
5A4 
(Novocastra) 
iAEP 3% 100% 100% 
Savic et al. 
2013 
41 NSCLC 
(c) selected 
5A4 
(Novocastra) 
Bond Polymer 
Refine 
37.5% 93% 96% 
To et al. 
2013 
373 adc (h) 5A4 
(Novocastra) 
- 6% 100% 100% 
Conklin et al. 
2013 
273 NSCLC 
(h) 
5A4 
(Novocastra) 
D5F3 (CST) 
ALK1 (Dako) 
Advance 
 
Advance 
Envision Flex + 
4%/4% 100% 
 
100% 
66% 
87.5% 
 
75% 
100% 
Sullivan et al. 
2013 
110 NSCLC 
(h/c) 
5A4 
(Novocastra) 
EnVision Flex + 6.4%/10% 100% 96% 
Houang et al. 
2014 
256 NSCLC 
(h/c) 
5A4 
(Novocastra) 
- 4% 100% 100% 
Cabillic et al 
2014 
3244 
NSCLC (h) 
5A4 
(Novocastra) 
Ultraview 4.6% 69% 83% 
Conde et al. 
2014 
103 NSCLC 
(h) selected 
5A4 
(Novocastra) 
D5F3 
(CST) 
Optiview - 98% 100% 
Demidova et 
al. 2014 
46 NSCLC 
(h) selected 
D5F3 
(CST) 
5A4 
(Novocastra) 
ALK1 (Dako) 
Bond Polymer 
Refine 
- 100% 
 
91% 
 
91% 
100% 
 
100% 
 
100% 
Hutarew et al. 
2014 
303 adc (h) ALK1 (Dako) 
5A4 
(Novocastra) 
D5F3 (CST) 
SP8 (Abcam) 
EnVision Flex 
EnVision Flex 
 
Optiview 
EnVision Flex 
4.5% 50% 
100% 
 
100% 
65% 
100% 
97% 
 
100% 
90% 
Alì et al. 
2014 
523 NSCLC 
(h) 
D5F3 
(CST) 
OptiView 3.8%/3.4% 90% 100% 
Wynes et al. 
2014 
100 NSCLC 
(h) selected 
D5F3 (CST) Optiview - 90% 95% 
Cha et al. 
2014 
330 adc (h) D5F3 (CST) OptiView 6%/7% 100% 100% 
Wang et al. 
2014 
430 adc (h) D5F3 
(CST) 
Optiview 10.7%/12.3% 100% 98% 
Personal 
experience 
154 adc 
(h/c) 
ALK1 
(Ventana) 
Optiview 7.8%/11.8% 100% 96% 
 
Abbreviations: adc, adenocarcinoma; NSCLC, non-small cell lung cancer; sqc, squamous cell carcinoma ; 
CST, Cell Signaling Technology; h, histology; c, cytology or cell block; IHC, immunohistochemistry; FISH, 
fluorescence in situ hybridization. 
Table 4. Summary of studies comparing ROS1 detection by IHC and FISH  
 
Reference Cases n Antibody 
Clone 
(Source) 
Detection  
System 
% FISH + & 
% IHC + 
Sensitivity 
 
Specificity 
Rimkunas et al. 
2012 
556 
NSCLC 
(h) 
D4D6 (CST) EnVision Flex+ 1.6%/1.6% 100% 100% 
Yoshida et al. 
2014 
270 adc 
(h) TMA 
D4D6 (CST) EnVision Flex+ - 94% 98% 
Sholl et al. 
2013 
220 adc 
(h) 
D4D6 (CST) - 1.2%/1.2% 100% 92% 
Mescam-
Mancini et al. 
2014 
121 adc  
(h) 
D4D6 (CST) UltraView 7.5% selected 
wild-type cases 
100% 98% 
Cha et al. 
2014 
330 adc 
(h) 
D4D6 (CST) OptiView 4%/8% 100% 98% 
 
Abbreviations: adc, adenocarcinoma; NSCLC, non-small cell lung cancer; sqc, squamous cell carcinoma ; 
CST, Cell Signaling Technology; h, histology; c, cytology or cell block; IHC, immunohistochemistry; FISH, 
fluorescence in situ hybridization; TMA, tissue microarray. 






